Wells Fargo & Company Downgrades PROCEPT BioRobotics (NASDAQ:PRCT) to Equal Weight

PROCEPT BioRobotics (NASDAQ:PRCT) was downgraded by Wells Fargo & Company from an “overweight” rating to an “equal weight” rating in a report released on Wednesday. They currently have a $19.00 target price on the stock. Wells Fargo & Company‘s target price points to a potential upside of 3.94% from the stock’s current price.

PRCT has been the subject of several other research reports. William Blair downgraded PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating in a research note on Wednesday. Evercore started coverage on shares of PROCEPT BioRobotics in a research note on Wednesday, June 24th. They issued an “outperform” rating and a $30.00 price objective on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research report on Friday, July 17th. Citigroup downgraded shares of PROCEPT BioRobotics to a “hold” rating in a report on Thursday, July 2nd. Finally, Truist Financial reiterated a “hold” rating and issued a $25.00 price target (down from $30.00) on shares of PROCEPT BioRobotics in a research report on Thursday, July 2nd. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, ten have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, PROCEPT BioRobotics currently has an average rating of “Hold” and an average price target of $32.09.

PROCEPT BioRobotics Price Performance

Shares of NASDAQ:PRCT opened at $18.28 on Wednesday. The firm has a market capitalization of $1.04 billion, a price-to-earnings ratio of -10.04 and a beta of 0.89. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.73 and a quick ratio of 5.51. The business’s 50 day simple moving average is $21.99 and its 200-day simple moving average is $24.97. PROCEPT BioRobotics has a 12 month low of $16.67 and a 12 month high of $49.90.

PROCEPT BioRobotics (NASDAQ:PRCT) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.01). The firm had revenue of $94.50 million during the quarter, compared to analysts’ expectations of $92.77 million. PROCEPT BioRobotics had a negative net margin of 31.82% and a negative return on equity of 27.70%. The business’s revenue for the quarter was up 19.3% on a year-over-year basis. During the same period in the previous year, the business earned ($0.35) earnings per share. As a group, equities analysts forecast that PROCEPT BioRobotics will post -1.53 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Advisory Services Network LLC boosted its stake in shares of PROCEPT BioRobotics by 1.3% during the 2nd quarter. Advisory Services Network LLC now owns 20,109 shares of the company’s stock worth $1,158,000 after purchasing an additional 250 shares during the last quarter. Osaic Holdings Inc. lifted its stake in shares of PROCEPT BioRobotics by 20.3% during the second quarter. Osaic Holdings Inc. now owns 2,001 shares of the company’s stock valued at $115,000 after buying an additional 337 shares during the period. ProShare Advisors LLC boosted its position in PROCEPT BioRobotics by 4.7% during the fourth quarter. ProShare Advisors LLC now owns 9,726 shares of the company’s stock worth $306,000 after acquiring an additional 438 shares during the last quarter. California State Teachers Retirement System boosted its position in PROCEPT BioRobotics by 1.4% during the second quarter. California State Teachers Retirement System now owns 49,446 shares of the company’s stock worth $2,848,000 after acquiring an additional 693 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its stake in PROCEPT BioRobotics by 436.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company’s stock worth $29,000 after acquiring an additional 746 shares during the period. 89.46% of the stock is currently owned by hedge funds and other institutional investors.

PROCEPT BioRobotics News Summary

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: Second-quarter revenue increased 19.3% year over year to $94.5 million, exceeding analysts’ estimate of $92.77 million. The company’s full-year 2026 revenue guidance of $390 million to $410 million has a midpoint broadly in line with the $397.2 million consensus forecast. PROCEPT BioRobotics Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Management discussed the company’s second-quarter performance and outlook on its earnings call, giving investors additional detail on demand trends, sales execution and the path toward improved profitability. PROCEPT BioRobotics Q2 2026 Earnings Call Transcript
• Negative Sentiment: PROCEPT reported a second-quarter loss of $0.47 per share, slightly worse than the expected $0.46 loss and wider than the $0.35 loss in the prior-year quarter. The company remains unprofitable, with a reported negative net margin and return on equity. PROCEPT BioRobotics Reports Q2 Loss, Beats Revenue Estimates
• Negative Sentiment: Multiple law firms have announced securities-fraud class actions alleging that PROCEPT overstated demand through late-quarter bulk discounts, channel stuffing or sales pull-ins, while failing to disclose excess customer inventory and weaker handpiece demand. The allegations are unproven, but the lawsuits increase legal, reputational and execution risks. A lead-plaintiff deadline of September 22, 2026 has been cited in several notices. PRCT Legal News

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.